Non-segmental vitiligo

A Phase II, multicenter, randomized study to evaluate safety and efficacy of topical AB1001 in adult patients with non-segmental vitiligo

Vitiligo skin carries a lower ultraviolet signature than non-melanoma skin cancers, and its epidermis shows a strong anti-skin cancer signature in miRNA networks. The long noncoding RNA MALAT1 and the microRNA miR-31-5p both protect melanin-deficient vitiligo keratinocytes against ultraviolet damage to DNA. An ANRF grant now funds an immune-competent 3D human skin model of vitiligo.

• Vitiligo and pigment biology

• Nevus of OtaJournal of the American Academy of Dermatology2026DOI
• microRNA miR-31-5p confers protection to melanin-deficient vitiligo keratinocytes against UV-B induced DNA damage by activating autophagy machineryScientific Reports2026DOI
• Minimal erythema dose variability in Indian skin: clinical implications across pigmentary and inflammatory dermatosesClinical and Experimental Dermatology2025Senior authorDOI
• Stem cell factor-mediated upregulation of SIRT1 protects melanin-deprived keratinocytes against UV-induced DNA damage in individuals with vitiligoThe FASEB Journal2024DOI
• Meta‐analysis reveals a lower ‘UV signature’ in vitiligo skin compared to non‐melanoma skin cancersExperimental Dermatology2024DOI
• VitiligoJournal of the American Academy of Dermatology2024Senior authorDOI

• Placebo-controlled · Sun PharmaSevere alopecia areata in adolescentsSubmitted to DCGI
• Phase 0 · Johnson & JohnsonMultibacillary leprosy, treatment monitoringOpens October 2026
• Observational · Systopic LaboratoriesHair health in adultsOpens October 2026
• Phase 4 · Johnson & JohnsonPsoriasisOpens November 2026
• Phase 3 · Johnson & JohnsonMultibacillary leprosyUnder way since January 2025
• Registry · PfizerAtopic dermatitis, alopecia areata and vitiligoStarted March 2025, completed